Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 526

1.

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2019 Oct 1. doi: 10.1038/s41375-019-0581-y. [Epub ahead of print]

PMID:
31576004
2.

Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells.

Mihajlović J, Diehl LAM, Hochhaus A, Clement JH.

J Cancer Res Clin Oncol. 2019 Sep 17. doi: 10.1007/s00432-019-03026-7. [Epub ahead of print]

PMID:
31531741
3.

Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.

Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, Schmieder K, Hochhaus A, Wenz F, Giordano FA.

Oncology. 2019 Sep 12:1-7. doi: 10.1159/000502483. [Epub ahead of print]

PMID:
31514200
4.

5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.

Gawlitza AL, Speith J, Rinke J, Sajzew R, Müller EK, Schäfer V, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Sep 10. doi: 10.1007/s00432-019-03016-9. [Epub ahead of print]

PMID:
31506740
5.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.

Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia E, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M.

Am J Hematol. 2019 Nov;94(11):1236-1243. doi: 10.1002/ajh.25628. Epub 2019 Sep 14.

PMID:
31456269
6.

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Haematologica. 2019 Aug 14. pii: haematol.2019.222323. doi: 10.3324/haematol.2019.222323. [Epub ahead of print]

7.

Not all cancer patients with an interest in CAM are the same. Differences between patients with a CAM interest prior to the cancer diagnosis and those with first-time interest since diagnosis.

Dubois C, Eisfeld H, Bauer F, Schmidt T, Kastrati K, Hochhaus A, Hübner J.

Complement Ther Med. 2019 Aug;45:167-171. doi: 10.1016/j.ctim.2019.06.009. Epub 2019 Jun 14.

PMID:
31331555
8.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
9.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
10.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2.

PMID:
30941573
11.

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient.

Frietsch JJ, Winkelmann N, Hunstig F, Schnetzke U, Hammersen FJ, Dönicke T, Lenz M, Gras F, Scholl S, Hochhaus A, Hilgendorf I.

Case Rep Oncol. 2019 Jan 4;12(1):22-28. doi: 10.1159/000495878. eCollection 2019 Jan-Apr.

12.

Importance of and Satisfaction with Information about Their Disease in Cancer Patients.

Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J.

J Cancer Educ. 2019 Jan 25. doi: 10.1007/s13187-019-1480-7. [Epub ahead of print]

PMID:
30684231
13.

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.

Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M.

Ann Hematol. 2019 Mar;98(3):713-722. doi: 10.1007/s00277-019-03621-1. Epub 2019 Jan 24.

PMID:
30680505
14.

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation.

Frietsch JJ, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U, Scholl S, Hochhaus A, Hilgendorf I.

Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019001. doi: 10.4084/MJHID.2019.001. eCollection 2019.

15.

Cancer patients' needs for virtues and physicians' characteristics in physician-patient communication: a survey among patient representatives.

Bartholomäus M, Zomorodbakhsch B, Micke O, Prott FJ, Rudolph I, Seilacher E, Hochhaus A, Huebner J.

Support Care Cancer. 2019 Aug;27(8):2783-2788. doi: 10.1007/s00520-018-4585-3. Epub 2018 Dec 6.

PMID:
30523413
16.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

17.

Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer.

Bauer F, Schmidt T, Eisfeld H, Dubois C, Kastrati K, Hochhaus A, Huebner J.

Complement Ther Med. 2018 Dec;41:105-110. doi: 10.1016/j.ctim.2018.09.008. Epub 2018 Sep 11.

PMID:
30477825
18.

Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry.

Hartung S, Rauh C, Hoang TNM, Jahreis S, Wagner K, Macheleidt J, Brakhage AA, Rummler S, Hochhaus A, von Lilienfeld-Toal M.

Cytometry A. 2019 Mar;95(3):332-338. doi: 10.1002/cyto.a.23653. Epub 2018 Nov 19.

PMID:
30450827
19.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. No abstract available.

PMID:
30285223
20.

[Chronic Myelogenous Leukemia].

Hochhaus A, Eigendorff E, Ernst T.

Dtsch Med Wochenschr. 2018 Sep;143(18):1304-1310. doi: 10.1055/s-0043-121023. Epub 2018 Sep 10. German.

PMID:
30199910
21.

Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.

Inselmann S, Wang Y, Saussele S, Fritz L, Schütz C, Huber M, Liebler S, Ernst T, Cai D, Botschek S, Brendel C, Calogero RA, Pavlinic D, Benes V, Liu ET, Neubauer A, Hochhaus A, Burchert A.

Cancer Res. 2018 Nov 1;78(21):6223-6234. doi: 10.1158/0008-5472.CAN-18-1477. Epub 2018 Aug 30.

PMID:
30166420
22.

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.

Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.

23.

Dasatinib.

Lindauer M, Hochhaus A.

Recent Results Cancer Res. 2018;212:29-68. doi: 10.1007/978-3-319-91439-8_2.

PMID:
30069624
24.

Human MAIT cells are rapidly activated by Aspergillus spp. in an APC-dependent manner.

Jahreis S, Böttcher S, Hartung S, Rachow T, Rummler S, Dietl AM, Haas H, Walther G, Hochhaus A, von Lilienfeld-Toal M.

Eur J Immunol. 2018 Oct;48(10):1698-1706. doi: 10.1002/eji.201747312. Epub 2018 Aug 13.

25.

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.

Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T; Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO).

Leukemia. 2018 Sep;32(9):2085-2087. doi: 10.1038/s41375-018-0214-x. Epub 2018 Jul 24. No abstract available.

PMID:
30042412
26.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

27.

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.

Ernst T, Busch M, Rinke J, Ernst J, Haferlach C, Beck JF, Hochhaus A, Gruhn B.

Leukemia. 2018 Sep;32(9):2046-2049. doi: 10.1038/s41375-018-0157-2. Epub 2018 Jun 13. No abstract available.

PMID:
29899367
28.

Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2018 Jun;558(7711):E5. doi: 10.1038/s41586-018-0164-5.

29.

Profiling neurotransmitters in a crustacean neural circuit for locomotion.

Schneider AC, Seichter HA, Neupert S, Hochhaus AM, Smarandache-Wellmann CR.

PLoS One. 2018 May 22;13(5):e0197781. doi: 10.1371/journal.pone.0197781. eCollection 2018.

30.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
31.

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kröger T, Ernst T, Kögler G, Krieg A, Lüdeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz FV, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J.

Blood. 2018 Jul 19;132(3):307-320. doi: 10.1182/blood-2017-10-810986. Epub 2018 May 3.

32.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
33.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

34.

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.

35.

Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.

Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Krüger WH, Hochhaus A, Sayer HG; East German Study Group for Hematology and Oncology (OSHO).

Bone Marrow Transplant. 2018 Sep;53(9):1188-1192. doi: 10.1038/s41409-018-0135-3. Epub 2018 Mar 15. No abstract available.

PMID:
29545592
36.

Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018.

Heidel FH, Gale RP, Hochhaus A.

Leukemia. 2018 May;32(5):1055-1056. doi: 10.1038/s41375-018-0079-z. Epub 2018 Feb 27. No abstract available.

PMID:
29515237
37.

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Böhmer FD.

Oncotarget. 2018 Jan 15;9(10):9442-9455. doi: 10.18632/oncotarget.24253. eCollection 2018 Feb 6.

38.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.

Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

39.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.

J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22.

40.

Therapy-free remission in chronic myeloid leukemia: possible mechanism.

Gale RP, Hochhaus A.

Expert Rev Hematol. 2018 Apr;11(4):269-272. doi: 10.1080/17474086.2018.1442213. Epub 2018 Mar 9. No abstract available.

PMID:
29448857
41.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

42.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A.

Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30.

PMID:
29381150
43.

The use of complementary and alternative medicine by patients in routine care and the risk of interactions.

Firkins R, Eisfeld H, Keinki C, Buentzel J, Hochhaus A, Schmidt T, Huebner J.

J Cancer Res Clin Oncol. 2018 Mar;144(3):551-557. doi: 10.1007/s00432-018-2587-7. Epub 2018 Jan 22.

PMID:
29356888
44.

Reply to K.R. Hoffman.

Cortes JE, Hochhaus A.

J Clin Oncol. 2017 Feb 10;35(5):567-568. doi: 10.1200/JCO.2016.70.2944. Epub 2016 Nov 14. No abstract available.

PMID:
29236618
45.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

46.

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188. doi: 10.1007/s00432-017-2532-1.

47.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

48.

Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.

Winkelmann N, Schäfer V, Rinke J, Kaiser A, Ernst P, Scholl S, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2511-2519. doi: 10.1007/s00432-017-2518-z. Epub 2017 Sep 14.

PMID:
28913558
49.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. doi: 10.1093/annonc/mdx219. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261.

PMID:
28881915
50.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

Supplemental Content

Loading ...
Support Center